0000000000791604

AUTHOR

Nelly Carpio

showing 3 related works from this author

Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving or…

2015

Studies that analyze the epidemiology and risk factors for invasive fungal disease (IFD) after engraftment in alloSCT are few in number. This single-center retrospective study included 404 alloSCT adult recipients surviving > 40 days who engrafted and were discharged without prior IFD. All patients who received >= 20 mg/day of prednisone were assigned to primary oral prophylaxis (itraconazole or low-dose voriconazole). The primary end point was the cumulative incidence (CI) of probable/proven IFD using the European Organization for Research and Treatment of Cancer and Mycoses Study Group (EORTC/MSG) criteria. The independent prognostic factors after multivariate analyses were used to constr…

MaleAntifungal AgentsTransplantation ConditioningPremedicationmedicine.medical_treatmentMULTICENTERAdministration OralHematopoietic stem cell transplantationEchinocandinsCOMPETING RISKCaspofunginRisk FactorsCause of DeathINFECTIONGranulocyte Colony-Stimulating FactorEPIDEMIOLOGYCumulative incidenceTreatment FailureFramingham Risk ScoreIncidenceIncidence (epidemiology)Hematopoietic Stem Cell TransplantationHematologyMiddle AgedAllograftsHematologic NeoplasmsVORICONAZOLEDrug Therapy CombinationFemaleASPERGILLOSISRisk assessmentFungemiamedicine.drugAdultmedicine.medical_specialtyNeutropeniaANTIFUNGAL PROPHYLAXISNeutropeniaRisk AssessmentITRACONAZOLEMedication AdherenceImmunocompromised HostLipopeptidesYoung AdultAmphotericin BInternal medicinemedicineAspergillosisHumansAgedRetrospective StudiesVoriconazoleTransplantationbusiness.industryRetrospective cohort studyFLUCONAZOLETriazolesmedicine.diseaseSurvival AnalysisSurgeryMycosesPatient CompliancebusinessSCT
researchProduct

Significance of increased blastic-appearing cells in bone marrow following myeloablative unrelated cord blood transplantation in adult patients.

2012

An abnormal increase of nonleukemic blastic-appearing lymphocytes in bone marrow (BM) specimens has been reported after unrelated cord blood transplantation (UCBT). This study analyzed the incidence, chronology, biological features, and clinical significance of elevated numbers of these cells in a series of 165 consecutive adult patients demonstrating myeloid engraftment after myeloablative UCBT in a single institution. The patients' BM samples were routinely evaluated by cytomorphology at different time points after UCBT. When ≥5% of blastic-appearing cells were detected by cytomorphology in the BM, samples were also evaluated by multiparametric flow cytometry to characterize these cells. …

AdultMalePathologymedicine.medical_specialtyAllogeneic Hematopoietic stem Cell TransplantMyeloidBone Marrow CellsTransplantation ChimeraCord Blood Stem Cell TransplantationHematogonesFlow cytometryInmune ReconstitutionBone MarrowmedicineHumansClinical significanceCumulative incidenceLymphocyte CountTransplantationTransplantation Chimeramedicine.diagnostic_testbusiness.industryIncidence (epidemiology)HematologyFetal BloodPrognosismedicine.anatomical_structureFemaleBone marrowCord Blood Stem Cell TransplantationbusinessBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
researchProduct

Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia

2019

We analyzed the outcomes of 26 consecutive patients with acquired severe aplastic anemia (SAA) undergoing peripheral blood stem cell transplantation (PBSCT) with partial ex vivo T cell depletion with a targeted T cell dose from HLA-identical sibling donors. The median patient age was 37 years (range, 3 to 63 years). Four patients with uncontrolled pneumonia at the time of transplantation died, on days +1, +2, +21, and +26. All evaluable patients engrafted, with a median time to neutrophil recovery of 11 days (range, 10 to 14 days) and a median time to platelet recovery of 19 days (range, 8 to 53 days). Two patients had transient grade I acute graft-versus-host disease (GVHD) with skin invol…

AdultMalemedicine.medical_specialtySevere aplastic anemiaAdolescentT-LymphocytesT cellGraft vs Host DiseaseHuman leukocyte antigenSeverity of Illness IndexGastroenterologyDisease-Free SurvivalLymphocyte DepletionHLA AntigensInternal medicinemedicineHumansCumulative incidenceSiblingChildAllogeneic stem cell transplantation Ex vivo T cell depletion Matched sibling donor Severe aplastic anemiaEx vivo T cell depletionMatched sibling donorPeripheral Blood Stem Cell TransplantationTransplantationbusiness.industryHistocompatibility TestingSiblingsAnemia AplasticHematologyMiddle AgedAllograftsmedicine.diseaseSevere Aplastic AnemiaTissue DonorsAllogeneic stem cell transplantationSurvival RateTransplantationPneumoniasurgical procedures operativemedicine.anatomical_structureChild PreschoolAcute DiseasebusinessEx vivoFollow-Up StudiesBiology of Blood and Marrow Transplantation
researchProduct